Abstract

BioNTech SE will announce its quarterly results on August 04, 2026 Pre-Market; this preview summarizes last quarter’s results, current-quarter forecasts for revenue, gross margin, net income or margin, and adjusted EPS with year-over-year comparisons, and compiles institutional views for investors’ reference.

Market Forecast

For the upcoming quarter, market forecasts point to revenue of 0.16 billion US dollars, EBIT of -0.63 billion US dollars, and adjusted EPS of -2.09 with estimated year-over-year changes of 5.96%, 7.46%, and -4.18%, respectively; company-level gross margin and net profit margin guidance was not disclosed. Last quarter’s actual baselines referenced in market models were revenue of 0.12 billion US dollars and adjusted EPS of -2.10, implying modest sequential growth expectations despite continued losses. BioNTech SE’s main business remains its COVID-19 vaccine franchise and other pipelines; models anticipate limited near-term top-line momentum while monitoring mix shifts. The segment with the greatest upside in consensus scenarios is non-COVID programs, as it scales from a smaller base; last quarter’s non-COVID revenue was 0.05 billion US dollars without explicit YoY disclosure.

Last Quarter Review

In the prior quarter, BioNTech SE reported revenue of 0.12 billion US dollars, a gross profit margin of 39.54%, GAAP net loss attributable to the parent company of 0.53 billion US dollars with a quarter-on-quarter change of -74.39%, and adjusted EPS of -2.10; revenue declined 35.39% year over year. A key financial highlight was revenue below model estimates, coupled with sustained investment in R&D that weighed on EBIT at -0.68 billion US dollars. Main business performance showed the COVID-19 vaccine contributed 0.07 billion US dollars while other revenue was 0.05 billion US dollars; YoY trends were not quantified.

Current Quarter Outlook

Main commercial revenue: COVID-19 franchise trajectory

The COVID-19 vaccine business remains the primary revenue driver, though scaled back from peak pandemic levels. Consensus expects revenue to stabilize around 0.16 billion US dollars this quarter, implying a low base and heightened sensitivity to seasonal booster demand and updated strain uptake. Margin dynamics are likely constrained by fixed manufacturing overheads and inventory management; with gross margin previously at 39.54%, incremental mix improvements or procurement timing could modestly affect profitability.

Most promising pipeline: non-COVID programs

Non-COVID revenue, which comprised approximately 0.05 billion US dollars last quarter, is positioned as the long-term growth vector. Street previews track milestone-based revenue and early commercialization contributions from oncology collaborations, though near-term revenue recognition remains uneven. This segment’s YoY growth could outpace the broader company once new trials deliver readouts and partner milestones trigger accruals, but its contribution this quarter is expected to remain smaller than COVID-19.

Key stock drivers this quarter

Three factors appear central to share performance into the print: revenue cadence versus the 0.16 billion US dollars consensus, operating expense discipline against an estimated EBIT loss of roughly 0.63 billion US dollars, and commentary on upcoming catalysts for oncology programs that shape medium-term revenue visibility. EPS sensitivity is significant given the negative leverage from operating costs; the consensus implies EPS of -2.09, and deviations will hinge on revenue timing and R&D phasing. Any updates on partnerships, milestone schedules, or regulatory timelines can pivot sentiment more than the headline P&L given the small current revenue base.

Analyst Opinions

Cautious views dominate recent previews, with a majority expecting continued operating losses and limited near-term revenue acceleration relative to consensus baselines. Analysts emphasize the risk that COVID-19 demand normalizes lower while non-COVID contributions ramp gradually, leaving EBIT near -0.63 billion US dollars and EPS near -2.09 this quarter. Several institutional commentaries highlight that upside could arise from better-than-expected booster uptake or milestone recognition in oncology collaborations, though the base case remains an extended transition period. Overall, the prevailing stance is cautious, prioritizing pipeline execution milestones and spending discipline as the main determinants of the stock’s path around August 04, 2026.